Geode Capital Management’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.39B Buy
15,437,251
+2,303,474
+18% +$193M 0.07% 231
2026
Q1
$1.05B Buy
13,133,777
+348,875
+3% +$28.8M 0.07% 265
2025
Q4
$1.08B Sell
12,784,902
-52,243
-0.4% -$4.29M 0.07% 240
2025
Q3
$993M Buy
12,837,145
+114,729
+0.9% +$8.96M 0.06% 266
2025
Q2
$990M Buy
12,722,416
+45,555
+0.4% +$3.4M 0.07% 252
2025
Q1
$915M Sell
12,676,861
-970,480
-7% -$69.5M 0.07% 248
2024
Q4
$1.01B Buy
13,647,341
+126,194
+0.9% +$8.83M 0.08% 219
2024
Q3
$889M Buy
13,521,147
+284,918
+2% +$20.7M 0.07% 249
2024
Q2
$1.22B Buy
13,236,229
+141,603
+1% +$12.5M 0.11% 162
2024
Q1
$1.25B Buy
13,094,626
+226,482
+2% +$19M 0.12% 157
2023
Q4
$978M Buy
12,868,144
+176,345
+1% +$12.3M 0.1% 179
2023
Q3
$877M Buy
12,691,799
+279,749
+2% +$22.5M 0.1% 176
2023
Q2
$1.17B Buy
12,412,050
+197,431
+2% +$17.2M 0.14% 126
2023
Q1
$1.01B Buy
12,214,619
+78,376
+0.6% +$6.16M 0.13% 135
2022
Q4
$904M Buy
12,136,243
+205,714
+2% +$15.9M 0.13% 155
2022
Q3
$985M Buy
11,930,529
+199,365
+2% +$19.2M 0.15% 123
2022
Q2
$1.11B Buy
11,731,164
+272,554
+2% +$28.2M 0.16% 111
2022
Q1
$1.35B Buy
11,458,610
+358,768
+3% +$40.2M 0.17% 104
2021
Q4
$1.43B Buy
11,099,842
+517,261
+5% +$60.3M 0.17% 101
2021
Q3
$1.19B Buy
10,582,581
+358,020
+4% +$40.9M 0.16% 112
2021
Q2
$1.06B Buy
10,224,561
+312,507
+3% +$29.5M 0.15% 121
2021
Q1
$827M Buy
9,912,054
+122,660
+1% +$10.4M 0.13% 138
2020
Q4
$891M Sell
9,789,394
-238,879
-2% -$19.8M 0.15% 124
2020
Q3
$799M Sell
10,028,273
-124,541
-1% -$9.72M 0.16% 119
2020
Q2
$700M Sell
10,152,814
-134,429
-1% -$9.55M 0.15% 133
2020
Q1
$646M Sell
10,287,243
-249,204
-2% -$18M 0.17% 123
2019
Q4
$818M Buy
10,536,447
+630,618
+6% +$49.2M 0.17% 113
2019
Q3
$725M Buy
9,905,829
+1,691,031
+21% +$119M 0.17% 113
2019
Q2
$505M Sell
8,214,798
-592,494
-7% -$35.8M 0.12% 165
2019
Q1
$561M Sell
8,807,292
-20,190
-0.2% -$1.15M 0.15% 130
2018
Q4
$450M Buy
8,827,482
+606,744
+7% +$30.7M 0.14% 143
2018
Q3
$476M Buy
8,220,738
+236,784
+3% +$11.6M 0.13% 144
2018
Q2
$387M Buy
7,983,954
+320,820
+4% +$15M 0.12% 166
2018
Q1
$356M Buy
7,663,134
+456,507
+6% +$19.8M 0.12% 179
2017
Q4
$270M Buy
7,206,627
+279,147
+4% +$10.2M 0.09% 223
2017
Q3
$252M Buy
6,927,480
+183,732
+3% +$7.01M 0.09% 218
2017
Q2
$265M Sell
6,743,748
-89,250
-1% -$3.26M 0.1% 196
2017
Q1
$214M Buy
6,832,998
+386,760
+6% +$12.1M 0.09% 237
2016
Q4
$201M Buy
6,446,238
+278,460
+5% +$9.02M 0.09% 218
2016
Q3
$248M Buy
6,167,778
+312,480
+5% +$11.8M 0.12% 166
2016
Q2
$194M Buy
5,855,298
+193,374
+3% +$6.62M 0.11% 199
2016
Q1
$166K Buy
5,661,924
+198,426
+4% +$5.48M 0.09% 225
2015
Q4
$144M Buy
5,463,498
+106,524
+2% +$2.77M 0.08% 250
2015
Q3
$127M Sell
5,356,974
-322,776
-6% -$7.79M 0.08% 267
2015
Q2
$135M Buy
5,679,750
+40,704
+0.7% +$919K 0.08% 263
2015
Q1
$134M Buy
5,639,046
+339,282
+6% +$7.61M 0.08% 272
2014
Q4
$112M Buy
5,299,764
+212,316
+4% +$4.27M 0.07% 303
2014
Q3
$86.5M Sell
5,087,448
-8,658
-0.2% -$137K 0.06% 338
2014
Q2
$72.9M Buy
5,096,106
+441,456
+9% +$5.98M 0.05% 385
2014
Q1
$57.5M Sell
4,654,650
-57,750
-1% -$666K 0.04% 430
2013
Q4
$51.6M Sell
4,712,400
-70,200
-1% -$791K 0.04% 448
2013
Q3
$55.5M Buy
4,782,600
+128,550
+3% +$1.5M 0.04% 400
2013
Q2
$52.1M Buy
+4,654,050
New +$55.1M 0.05% 387

Other funds holding EW

Geode Capital Management's EW Position: Q2 2026 in Review

Geode Capital Management increased its Edwards Lifesciences (EW) stake by 18% in Q2 2026, buying an estimated $193M and bringing the position to 15,437,251 shares worth $1.39B. The position accounts for 0.07% of the portfolio, ranked #231.

Geode Capital Management first reported a position in EW in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.43B in Q4 2021. 1,096 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Geode Capital Management held 15,437,251 shares of Edwards Lifesciences worth $1.39B as of Q2 2026.
  • Geode Capital Management bought 2,303,474 Edwards Lifesciences shares in Q2 2026, an estimated $193M.
  • Edwards Lifesciences made up 0.07% of Geode Capital Management's portfolio in Q2 2026, its #231 holding.
  • Geode Capital Management first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 53 quarters since.
  • Geode Capital Management's Edwards Lifesciences position peaked at $1.43B in Q4 2021.
  • 1,096 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.